GW Pharmaceuticals

Chain Bridge I (NASDAQ:CBRG) announced on Monday the acquisition of Phytanix Bio, a pharmaceutical company specializing in the development of therapeutics based on cannabinoid and cannabinoid-like molecules. The transaction, valued at $58 million, also includes the assumption of preferred stock and...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals have begun construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne, UK, with an investment of over $100 million.  The new facility, expected to be...

Neptune Revenue Declines 63% YoY, Shifts To CPG And Branded Products Global health and wellness company Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) revealed Monday its third-quarter financial results, on the heels of announcing the purchase of a 50.1% stake in baby food and...

Epidyolex, the first FDA approved CBD medicine for severe epilepsy in children, received Australian Therapeutic Goods Administration approval. GW Pharmaceuticals plc (NASDAQ: GWPH) confirmed Wednesday that TGA authorized the medicine to treat Lennox-Gastaut syndrome (LGS) or Dravet...

The race for a novel coronavirus vaccine has lit a fuse under biotech and pharmaceutical companies. 2020 will surely be remembered as the year of COVID-19 and an unprecedented boom for these industries. During good times, pharma stocks are attractive because of their steady cash flow, high-profit...

Less than a week after its most recent update on GW Pharmaceuticals plc (NASDAQ: GWPH), Cantor Fitzgerald lowered its price target for the stock Monday after the issuance of the company's 10-K report.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW...

GW Pharmaceuticals plc (NASDAQ: GWPH) Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW Pharmaceuticals with a $211 price...

Benzinga has featured a look at many investor favorite stocks over the past week. Some recent posts took a look back at the past year. Many others were forward focused, including forecasts for the top tech darling. The end of the year is nearly upon us. As it does every week, Benzinga...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) lost more than 58 percent of their value Monday morning after the company reported disappointing results from its phase 2 STAR 1 clinical trial for its adult epilepsy treatment. Zynerba is one of the largest cannabinoid-focused pharmaceutical...

Elemer Piros of Cantor Fitzgerald maintained an Overweight rating and $208 price target on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) after the developer of cannbinoid products reported its fiscal second-quarter results. Piros' main takeaway from the report and conference call is that GW...

Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a developer of cannabinoid prescription medicines, spiked by more than 10 percent Monday morning following the company's announcement that Epidiolex achieved a primary endpoint in a Phase 3 clinical study. Epidiolex, GW Pharma's lead...

Shares of GW Pharmaceuticals PLC - ADR (NASDAQ: GWPH) soared Wednesday from around $83 per share to close at $104.03 after Reuters reported the company is in talks with an investment banks to consider strategic alternatives. GW Pharmaceuticals is a developer of marijuana-based epilepsy...

Shares of GW Pharmaceuticals PLC - ADR (NASDAQ: GWPH) spiked higher by more than 5 percent early Thursday morning after the company reported that data from a physician-led study into Epidiolex "reduced seizure frequency" across multiple drug-resistant epilepsy syndromes and seizure types and was "...

Richard Nixon declared it public enemy number one. The Reagan administration told citizens to 'just say no.' But among the long-running 'war' on drugs, reality has risen to the top, particularly when it comes to marijuana. Still, even the president keeps his words slightly...